|| Checking for direct PDF access through Ovid
Snakebite causes a large amount of morbidities and mortalities in Africa. The safety, efficacy, and homogeneity of anti-snake venoms are crucial for snakebite treatments to be effective with minimal adverse effects. We assessed the homogeneity of preparations of three different batches of Combipack snake venom antiserums (Pan Africa) [CSVAPA] by quantitatively analysing F(ab’)2, IgG, and other contaminating proteins of plasma. LC-MS/MS analysis showed that approximately 92.4% of the proteins from the CSVAPA samples was IgG/F(ab’)2 and the percent composition of contaminating proteins in CSVAPA varied from 0.07 to 4.6%. Batch 1 of the CSVAPA also contained a minor amount of undigested IgG and F(ab’)2 aggregates. CSVAPA contained more than 60% venom-specific antibodies, showed moderate complement activation, no IgE contamination, safe level of endotoxin, and also showed pre-clinical safety. The immuno cross-reactivity of CSVAPA against 14 Viperidae and Elapidae snake venoms of Africa was tested by ELISA and immunoblotting, and the neutralization of major enzymatic venom activities, demonstrating that high molecular weight (>50kDa) venom proteins are better recognized/neutralized compared to relatively low molecular weight (<20kDa) venom proteins. CSVAPA at a dose of 3–12 times higher than the clinical dose did not cause deaths or adverse reaction of treated rabbits. The results suggest the satisfactory quality, safety, and efficacy of CSVAPA.CSVAPA comprises mostly F(ab’)2; batch 1 contained minor amount of undigested IgG.92.4% of proteins in CSVAPA samples are IgG/F(ab’)2.Endotoxin, albumin and cresol were in safe limits and CSVAPA was devoid of IgE.In vivo toxicity study suggests preclinical safety of CSVAPA.CSVAPA contain >60% venoms-specific antibodies.